alpha-aminopyridine has been researched along with bortezomib in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daud, A; Munster, P; Spriggs, DR | 1 |
| Cui, YS; Fang, BJ; Liu, LN; Liu, YZ; Song, YP; Wang, DY | 1 |
| Chen, Y; Tong, J; Wang, Y; Wu, Y; Xiang, R; Xu, W; Yan, H; Yu, W; Zhang, N | 1 |
| Kimura, S; Kojima, K; Maeda, A; Nishida, Y; Yoshimura, M | 1 |
| Chen, X; Dong, Y; Feng, J; Shu, M; Tang, H; Xu, L | 1 |
| Moore, DC; Muslimani, A; Nelson, V | 1 |
| Chen, X; Duan, Y; Huang, H; Jiang, Y; Jin, Z; Li, C; Wang, Q; Wu, D; Xu, T; Zhu, Q | 1 |
| Chen, GH; Fu, CC; Liu, W; Liu, Y; Wu, DP; Xie, Y; Xu, Y; Yan, LZ; Yan, S; Yao, WQ | 1 |
1 review(s) available for alpha-aminopyridine and bortezomib
| Article | Year |
|---|---|
New drugs in gynecologic cancer.
Topics: Aminopyridines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cisplatin; Female; Gefitinib; Genital Neoplasms, Female; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Organoplatinum Compounds; Paclitaxel; Protein-Tyrosine Kinases; Pyrazines; Quinazolines; Trastuzumab | 2001 |
7 other study(ies) available for alpha-aminopyridine and bortezomib
| Article | Year |
|---|---|
[Successful treatment of one case with relapsed refractory multiple myeloma by chidamide in combination with bortezomib and dexamethasone].
Topics: Aminopyridines; Benzamides; Bortezomib; Dexamethasone; Humans; Multiple Myeloma | 2016 |
Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
Topics: Aminopyridines; Animals; Apoptosis; Bortezomib; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Inhibitory Concentration 50; Mice; Morpholines; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma.
Topics: Aminopyridines; Apoptosis; Bortezomib; Cell Line, Tumor; Dipeptides; Doxorubicin; Genes, p53; Humans; Imidazoles; Lymphoma, Mantle-Cell; Phosphorylation; Piperazines; Prognosis; Protein Phosphatase 2C; Signal Transduction | 2016 |
Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Autophagy; Benzamides; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Epigenomics; Female; Histone Deacetylases; Humans; Mice; Mice, Nude; Microscopy, Electron, Transmission; Multiple Myeloma | 2020 |
Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma.
Topics: Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Multiple Myeloma; Triazines | 2021 |
Clinical features and treatment outcomes of 14 patients with hepatosplenic γ δ T-cell lymphoma.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bortezomib; Cyclophosphamide; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Intraepithelial Lymphocytes; Liver Neoplasms; Lymphoma, T-Cell, Peripheral; Middle Aged; Prednisolone; Retrospective Studies; Splenic Neoplasms; Treatment Outcome; Vincristine; Young Adult | 2021 |
[The Effects of Chidamide Combined with Anti-myeloma Drugs on the Proliferation and Apoptosis of Myeloma Cells].
Topics: Aminopyridines; Apoptosis; Benzamides; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Pharmaceutical Preparations | 2021 |